Cost-effectiveness of chronic hepatitis C treatment in Spain;Coste-eficacia del tratamiento de la hepatitis C crónica en España

Gastroenterologia y Hepatologia

Volumn 32, Issue 7, 2009, Pages 472-482

  Haj Ali Saflo, Okba ^a   Hernández Guijo, Jesús Miguel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Efficacy cost; Hepatitis C; Interferon; Pegylated interferon alpha 2a; Pegylated interferon alpha 2b; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL RESISTANCE; ASCITES; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; REVIEW; SPAIN;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; SPAIN;

EID: 67650976335     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.01.181     Document Type: Review

References (35)

1. Bruguera M., and Forns X. Hepatitis C en España. Medicina Clínica 127 (2006) 113-117
2. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
3. Fried M.W., Shiffman M.L., Redd K.R., Smith C., Marinos G., and Gonçales Jr. F.L. Peginterferon-α2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 347 (2002) 975-982
4. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
5. Berg T., Von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
6. Sánchez-Tapias J.M., Diago M., Escarpín P., Enríquez J., Romero-Gómez M., Bárcena R., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006) 451-460
7. Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694
8. Ferenci P., Forman E., Laferl H., Gschwantler M., Hackl F., Brunner H., et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. Journal of Hepatology 44 (2006) 275-282
9. Jacobson I.M., Brown Jr. R.S., McCone J., Black M., Albert C., Dragutsky M.S., et al. WIN-R Study Group. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 46 (2007) 982-990
10. Mangia A., Minerva N., Cozzolongo R., Ricci G.L., Carretta V., Vinelli F., et al. Individualizad treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 47 (2008) 43-50
11. Fried M.W., Jensen D.M., Rodriguez-Torres M., Nyberg L.M., Di Bisceglie A.M., Morgan T.R., et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 48 (2008) 1033-1043
12. Angelico M., Koehler-Horst B., Piccolo P., Angelico F., Gentile S., Francioso S., et al. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: The SMIEC II trial in naïve patients with chronic hepatitis C. European Journal of Gastroenterology and Hepatology 20 (2008) 680-687
13. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology 44 (2006) 97-103
14. Ferenci P., Forman E., Laferl H., Gschwantler M., Hackl F., Brunner H., et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. Journal of Hepatology 44 (2006) 275-282
15. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006) 954-960
16. Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 47 (2008) 1884-1893
17. Dalgard O., Bjøro K., Hellum K.B., Myrvang B., Ritland S., Skaug K., et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 40 (2004) 1260-1265
18. Mangia A., Santero R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. The New England Journal of Medicine 352 (2005) 2609-2617
19. Von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129 (2005) 522-527
20. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Solá R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. The New England Journal of Medicine 357 (2007) 124-134
21. Powis J., Peltekian K.M., Lee S.S., Sherman M., Bain V.G., Cooper C.c., et al. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. Journal of Viral Hepatitis 15 (2008) 52-57
22. Ming-Lung Y., Chia-Yen D., Jee-Fu H., Nai-Jen H., Li-Po L., Ming-Yen H., et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 (2007) 553-559
23. Weiland O., Hollander A., Mattsson L., Glaumann H., Lindahl K., Schvarcz R., et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. Journal of Viral Hepatitis 15 (2008) 641-645
24. Kamal S.M., El Tawil A.A., Nakano T., He Q., Rasenack J., Hakam S.A., et al. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 54 (2005) 858-866
25. Derbala M.F., Al Kaabi S.R., El Dweik N.Z., Pasic F., Butt M.T., Yakoob R., et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology 12 (2006) 5692-5698
26. López-Alonso G., Ágeda M., Devesa M.J., Cuenca F., Suárez A., Ortega L., et al. Results of the treatment of chronic hepatitis C genotype 4. A comparative analysis with genotype 1. Revista Española de Enfermedades Digestivas 100 (2008) 208-211
27. Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner H., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135 (2008) 451-458
28. Di Bisceglie A.M., Ghalib R.H., Hamzeh F.M., and Rustgi V.K. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis 14 (2007) 721-729
29. Escudero A., Rodríguez F., Serra M.A., Del Olmo J.A., Montes F., and Rodrigo J.M. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study. Journal of Gastroenterology and Hepatology 23 (2008) 861-866
30. Silva M., Poo J., Wagner F., Jackson M., Cutler D., Grace M., et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology 45 (2006) 204-213
31. Malone D.C., Tran T., and Poordad F. Cost-efficacy analisis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. Journal of Managed Care Pharmacy 11 (2003) 687-694
32. Shepherd J., Jones J., Davidson P., Price A., and Waugh N. Interferon alfa (pegylated and non-pegylated) and ribavirina for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technology Assessment 11 (2007) 51-87
33. Scotto G., Fazio V., Fornabaio C., Tartaglia A., Di Tullio R., Saracino A., et al. Peg-Interferon alpha-2a versus Peg-Interferon alpha-2b in nonresponders with HCV active chronic hepatitis: A pilot study. Journal of Interferon & Cytokine Research 28 (2008) 623-630
34. Sacristán J.A., Oliva J., Del Llano J., Prieto L., and Pinto J.L. ¿Qué es una tecnología sanitaria eficiente en España?. Gaceta Sanitaria 16 (2002) 334-343
35. Davis G.L., Albright J.E., Cook S.F., and Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transplantation 9 (2003) 331-338